Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Acumen Pharma
View:
Post by FarmerBetty on Oct 18, 2022 4:27pm

Acumen Pharma

A friend asked me why are people not aware of the timeline it takes to acquire phase 1 results in the clinic? Acumen is the company Promis had on it's corporate presentations until the bottom fell out off the Nasdaq. 

ACU193 - Is the first immunotherapy drug candidate to enter the clinic that was developed to target toxic ABO's. Closest technology to Promis! Highlights off of Acumen's website.

Aug 16,2021- We anticipate study ACU-001 recruitment and cohort progression will allow us to provide topline results.....by year end 2022.

Oct 7, 2021- Accumen announces first patient dose.

Mar 28, 2022- Currently enrolling topline results now expected first half of 2023.

Clinical Trials. Gov. Recruitment status : Recruiting, first posted Jun 18,2021, Last updated Oct 10, 2022.

Estimated enrollment - 62 participants
Actual study start: Jun 21, 2021
Estimated primary completion date: Mar 2023
Estimated study completion date: Jun 2023
Comment by retiredcop on Oct 18, 2022 4:49pm
First doses willgoto paid individuals...usually university or med students 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities